CN101951991A - 用于治疗缺血性心脏病的3-(2，2，2-三甲基肼)丙酸盐的盐 - Google Patents
用于治疗缺血性心脏病的3-(2，2，2-三甲基肼)丙酸盐的盐 Download PDFInfo
- Publication number
- CN101951991A CN101951991A CN200880119405XA CN200880119405A CN101951991A CN 101951991 A CN101951991 A CN 101951991A CN 200880119405X A CN200880119405X A CN 200880119405XA CN 200880119405 A CN200880119405 A CN 200880119405A CN 101951991 A CN101951991 A CN 101951991A
- Authority
- CN
- China
- Prior art keywords
- hydrazine
- propionate
- koji
- rice
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 claims description 19
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 claims description 17
- 210000002216 heart Anatomy 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 3
- DSMFFOSDNKPHJP-TYYBGVCCSA-N (e)-but-2-enedioic acid;propanoic acid Chemical compound CCC(O)=O.OC(=O)\C=C\C(O)=O DSMFFOSDNKPHJP-TYYBGVCCSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 1
- KSHRIBUREVIIFI-UHFFFAOYSA-N phosphoric acid;propanoic acid Chemical compound CCC(O)=O.OP(O)(O)=O KSHRIBUREVIIFI-UHFFFAOYSA-N 0.000 abstract 1
- JHCKVPVXWBVGDI-UHFFFAOYSA-N hydrazine;dihydrate Chemical compound O.O.NN JHCKVPVXWBVGDI-UHFFFAOYSA-N 0.000 description 15
- 208000028867 ischemia Diseases 0.000 description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- BFKLIGQXXNIIEL-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrazine Chemical compound NN.OC(=O)\C=C\C(O)=O BFKLIGQXXNIIEL-TYYBGVCCSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003293 cardioprotective effect Effects 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- VFTOLAKHPLTCIF-UHFFFAOYSA-N aminoazanium;dihydrogen phosphate Chemical compound NN.OP(O)(O)=O VFTOLAKHPLTCIF-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960002937 meldonium Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及通过3-(2，2，2-三甲基肼)丙酸盐氢富马酸盐和3-(2，2，2-三甲基肼)丙酸盐二氢磷酸盐来高效治疗缺血性心脏病。
Description
技术领域
本发明涉及3-(2，2，2-三甲基肼)丙酸盐氢富马酸盐和3-(2，2，2-三甲基肼)丙酸盐二氢磷酸盐在治疗缺血性心脏病中的应用。
背景技术
心肌梗死是由长时间缺血引起心肌不可逆坏死的一种病症。
心肌梗死(心脏病发作)是冠心病的严重结果。心肌梗死(MI)是由长时间缺血所继发的心肌不可逆坏死。心脏病发作或心肌梗死是医学突发事件，其中供给心脏的血液突然且急剧地减少或阻断，导致心肌因缺氧而死亡。每年有超过110万人经历心脏病发作(心肌梗死)，其中有许多人，其心脏病发作是冠心病的最初症状。心脏病发作可严重到足以引起死亡，或者根本不发作。每五个人中仅一人有轻微症状，或完全没有症状，且只有在一段时间后通过常规心电图才能发现心脏病发作。
心脏病发作(心肌梗死)通常由阻塞心脏动脉的血块引起。动脉壁上的脂肪沉积物通常已使动脉变狭窄。这些沉积物可破裂或破开，降低血流，并释放使血小板粘稠且更易形成凝块的物质。有时，凝块形成在心脏内部，随后脱离并粘在通向心脏的动脉中。这些动脉中某个发生痉挛会引起血流停止。
已知3-(2，2，2-三甲基肼)丙酸盐二水合物是具有心脏保护性质的化合物(此物质的国际非专属名称是米曲肼二水合物)。3-(2，2，2-三甲基肼)丙酸盐公开在US 4481218(INST ORGANICHESKOGO SINTEZA)06.11.1984中。
已知3-(2，2，2-三甲基肼)丙酸盐作为二水合物被广泛用于控制体内肉毒碱和γ-丁基甜菜碱浓度比和随后脂肪酸β-氧化的速度。DAMBROVA M.，LIEPINSH E.，KALVINSH I.I.Mildronate：cardioprotective action throughcarnitine-lowering effect.Trends in Cardiovascular Medicine，.2002，vol.12，no.6，p.275-279。
由于这些性质，米曲肼二水合物被广泛用在医学中以作为抗缺血、应力保护和心脏保护药物来治疗各种心血管疾病和包括组织缺血的其它病状。KARPOV R.S.，KOSHELSKAYA O.A.，VRUBLEVSKY A.V.，SOKOLOV A.A.，TEPLYAKOV AT.，SKARDA I.，DZERVE V.，KLINTSARE D.，VITOLS A.，KALNINS U.，KALVINSH I.，MATVEYA L.，URBANE D..Clinical Efficacyand Safety of Mildronate in Patients With Ischemic Heart Disease and ChronicHeart Failure.Kardiologiya.2000，no.6，p.69-74。在心血管疾病的治疗中，3-(2，2，2-三甲基肼)丙酸盐的作用机制基于对肉毒碱生物合成速率的限制并涉及通过线粒体膜的长链脂肪酸转运的限制。SIMKHOVICH B.Z.，SHUTENKOZ.V.，MEIRENA D.V.，KHAGI K.B.，MEZHAPUKE R.J.，MOLODCHINA T.N.，KALVINS I.J.，LUKEVICS E.3-(2，2，2，-Trimethylhydrazinium)propionate(THP)-a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotectiveproperties.Biochemical Pharmacology.1988，vol.37，p.195-202.，KIRIMOTOT.，ASAKA N.，NAKANO M.，TAJIMA K.，MIYAKE H.，MATSUURA N.Beneficial effects of MET-88，a γ-butyrobetaine hydroxylase inhibitor in rats withheart failure following myocardial infarction.European Journal ofPharmacology.2000，vol.395，no.3，p.217-224。
WO 00/003063A(SIGMA TAU IND FARMACEUTI)02.06.2000专利公开了L-肉毒碱酸富马酸盐(L-carnitine acid fumarate)和其烷酰基衍生物在制备组合物中的应用，所述组合物适用于在大范围使用者和/或患者中降低器官缺血发生的风险以及预防和/或治疗器官缺血，特别是影响心脏循环的器官。L-肉毒碱和米曲肼二水合物在结构上非常类似。然而，米曲肼二水合物的药理作用却对抗L-肉毒碱的作用。因此，将逆转录酶抑制剂与米曲肼二水合物结合对本领域技术人员并非显而易见的。
作为比米曲肼二水合物更稳定的物质，米曲肼的氢富马酸盐和二氢磷酸盐公开于EP 1667960A(JOINT STOCK COMPANY GRINDEKS)14.06.2006。
发明内容
已知米曲肼二水合物用于治疗缺血性心脏病；然而没有资料显示米曲肼的盐用于治疗缺血性心脏病。
出乎我们意料，通过在心肌梗死和/或缺血治疗中使用米曲肼氢富马酸盐，其显示出意想不到的效果，且在体内心肌缺血模型中比米曲肼二水合物更有效。米曲肼的氢富马酸盐和二氢磷酸盐是药学上可接受的盐，与米曲肼二水合物是生物等效的，应显示出与米曲肼二水合物相同的医学作用，但却意想不到地显示出比米曲肼二水合物在统计学上更好的疗效。
本发明的最佳实施方式
以下实施例进一步举例说明本发明。
抗缺血活性
实验在初始体重为300-350g的成年雄性Wistar大鼠上进行。在实验期间，将动物以每组8只置于标准条板箱中。饲料是标准的膳食R70(LABFOR，Lactamin AB，Sweden)。保持室温在21-23℃，相对湿度在65±10％，12小时光/暗循环。
实验步骤根据欧洲共同体准则和地方法律和规则进行，并得到拉脱维亚动物保护伦理委员会，食物和兽医服务机构(Latvian Animal Protection EthicalCommittee，the Food and Veterinary Service)的许可。
实验1
体内心肌梗死
将约300g重的大鼠随机分为4组，每组8只。第一组口服盐水(对照组)，第二组口服100mg/kg米曲肼二水合物，第三组口服100mg/kg米曲肼氢富马酸盐，第四组口服100mg/kg米曲肼二氢磷酸盐，持续14天。
将大鼠用戊巴比妥钠麻醉(60mg/kg，腹腔注射)。对它们插管，并以55次呼吸/分钟的呼吸速率用15ml/kg室内空气通过啮齿类呼吸器(RodentVentilator 7025，Ugo Basile，Itally)人工呼吸。
需要时，通过切断第四和第五根肋骨在胸骨的左侧开胸。打开心包，将5/0聚丙烯缝合线(Surgipro II，Syneture)从左前降冠状动脉下通过，并穿过小塑料管以允许冠状动脉的可逆闭合。冠状流量使用来自ADInstruments的超声流量检测器(HSE)和PowerLab 8/30系统测量。
通过收缩穿过塑料管的线来进行闭合。
在120分钟再灌注结束时，再灌注后，将心脏切下并在50mm Hg的恒定压力下经由大动脉逆向灌注37℃、pH 7.3-7.5、充氧的Krebs-Henseleit缓冲液(含量以mmol/L计：NaCl 118、CaCl22.52、MgCl21.64、NaHCO324.88、KH2PO41.18、葡萄糖10.0、EDTA 0.05)。在10分钟后，将左前降冠状动脉松开，并将风险区用经由大动脉根灌输的4ml 0.1％亚甲蓝溶液的Krebs-Henseleit缓冲液标出。将心脏从顶端到底部以2mm厚度横切，并在1％氯化三苯基四氮唑的磷酸盐缓冲溶液(pH 7.4，37℃)中孵育10分钟，以将活组织染红和将坏死组织染白。随后，将右心室切下，并用Minolta 7D相机对左心室切片拍照。使用Image-Pro Plus 4.5.1软件对照片进行计算机化平面计量分析，以确定风险面积(AR)和坏死面积(AN)，将其表示为左心室(LV)的百分数。随后，根据以下公式，使用所得数值计算梗塞大小(IS)，将其表示为风险面积的百分数。
通过持续14天施用米曲肼二水合物、米曲肼氢富马酸盐和米曲肼二氢磷酸盐的体内心肌梗死的结果总结在表1中。
表1
体内心肌梗死的结果
| 风险面积/左心室面积 | 基于风险面积的坏死面积％ | 基于对照的梗塞大小％ | |
| 对照 | 52.0±2.5 | 64.3±2.7 | 100.0±4.1 |
| 米曲肼二水合物 | 58.0±2.2 | 64.0±2.7 | 99.0±4.2 |
| 米曲肼氢富马酸盐 | 62.0±3.5 | 52.2±4.3*# | 81.0±6.6*# |
| 米曲肼二氢磷酸盐 | 57.0±3.0 | 50.9±2.6*# | 79.0±4.1*# |
与对照组相比*p＜0.01；与米曲肼二水合物组相比#p＜0.01。
Claims (5)
1.3-(2，2，2-三甲基肼)丙酸盐的盐在制备治疗缺血性心脏病的药物中的应用，所述3-(2，2，2-三甲基肼)丙酸盐的盐选自由二氢磷酸盐和氢富马酸盐组成的组。
2.一种3-(2，2，2-三甲基肼)丙酸盐的盐，其用于治疗缺血性心脏病。
3.如权利要求1或2所述的应用，其中所述缺血性心脏病是心肌梗死。
4.如权利要求1至3中任一项所述的3-(2，2，2-三甲基肼)丙酸盐的盐，其中所述3-(2，2，2-三甲基肼)丙酸盐的盐是3-(2，2，2-三甲基肼)丙酸盐氢富马酸盐。
5.如权利要求1至3中任一项所述的3-(2，2，2-三甲基肼)丙酸盐的盐，其中所述3-(2，2，2-三甲基肼)丙酸盐的盐是3-(2，2，2-三甲基肼)丙酸盐二氢磷酸盐。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122359 | 2007-12-05 | ||
| EP07122360.6 | 2007-12-05 | ||
| EP07122359.8 | 2007-12-05 | ||
| EP07122360 | 2007-12-05 | ||
| PCT/EP2008/066712 WO2009071586A2 (en) | 2007-12-05 | 2008-12-03 | 3-(2,2,2-trimethylhydrazinium) propionate salts for treating ischemic heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101951991A true CN101951991A (zh) | 2011-01-19 |
Family
ID=40364183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880119405XA Pending CN101951991A (zh) | 2007-12-05 | 2008-12-03 | 用于治疗缺血性心脏病的3-(2，2，2-三甲基肼)丙酸盐的盐 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20110028438A1 (zh) |
| EP (1) | EP2222376B1 (zh) |
| JP (1) | JP2011506285A (zh) |
| KR (1) | KR20100084687A (zh) |
| CN (1) | CN101951991A (zh) |
| AR (1) | AR069548A1 (zh) |
| AT (1) | ATE503473T1 (zh) |
| AU (1) | AU2008333263A1 (zh) |
| BR (1) | BRPI0819055A2 (zh) |
| CA (1) | CA2706357C (zh) |
| CL (1) | CL2008003552A1 (zh) |
| CO (1) | CO6280507A2 (zh) |
| DE (1) | DE602008005930D1 (zh) |
| DK (1) | DK2222376T3 (zh) |
| DO (1) | DOP2010000162A (zh) |
| EA (1) | EA016971B1 (zh) |
| GE (1) | GEP20125646B (zh) |
| HR (1) | HRP20110468T1 (zh) |
| IL (1) | IL205962A0 (zh) |
| MA (1) | MA31992B1 (zh) |
| MX (1) | MX2010006257A (zh) |
| MY (1) | MY158799A (zh) |
| NZ (1) | NZ586518A (zh) |
| PA (1) | PA8806001A1 (zh) |
| PE (1) | PE20091209A1 (zh) |
| PL (1) | PL2222376T3 (zh) |
| PT (1) | PT2222376E (zh) |
| RS (1) | RS51785B (zh) |
| SI (1) | SI2222376T1 (zh) |
| SV (1) | SV2010003585A (zh) |
| TN (1) | TN2010000249A1 (zh) |
| TW (1) | TWI391131B (zh) |
| UA (1) | UA100249C2 (zh) |
| UY (1) | UY31499A1 (zh) |
| WO (1) | WO2009071586A2 (zh) |
| ZA (1) | ZA201003640B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55092B1 (sr) * | 2011-04-27 | 2016-12-30 | Grindeks Jsc | Upotreba 3-karboksi-n-etil-n,n-dimetilpropan-1-aminijum soli u lečenju kardiovaskularne bolesti |
| RU2457198C1 (ru) * | 2011-05-31 | 2012-07-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью |
| RU2467748C1 (ru) * | 2011-08-08 | 2012-11-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1829683A (zh) * | 2003-08-04 | 2006-09-06 | 联合股份公司格林代克斯 | 米屈肼盐及其制备方法以及基于米屈肼盐的药物组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE386014T1 (de) * | 2003-08-04 | 2008-03-15 | Grindeks Jsc | Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung |
-
2008
- 2008-11-26 TW TW097145679A patent/TWI391131B/zh not_active IP Right Cessation
- 2008-11-27 PE PE2008001983A patent/PE20091209A1/es not_active Application Discontinuation
- 2008-11-28 CL CL2008003552A patent/CL2008003552A1/es unknown
- 2008-11-28 PA PA20088806001A patent/PA8806001A1/es unknown
- 2008-11-28 UY UY31499A patent/UY31499A1/es not_active Application Discontinuation
- 2008-12-02 AR ARP080105238A patent/AR069548A1/es unknown
- 2008-12-03 DE DE602008005930T patent/DE602008005930D1/de active Active
- 2008-12-03 UA UAA201006836A patent/UA100249C2/uk unknown
- 2008-12-03 CN CN200880119405XA patent/CN101951991A/zh active Pending
- 2008-12-03 EA EA201000739A patent/EA016971B1/ru unknown
- 2008-12-03 MY MYPI2010002604A patent/MY158799A/en unknown
- 2008-12-03 NZ NZ586518A patent/NZ586518A/en not_active IP Right Cessation
- 2008-12-03 BR BRPI0819055 patent/BRPI0819055A2/pt not_active IP Right Cessation
- 2008-12-03 US US12/734,785 patent/US20110028438A1/en not_active Abandoned
- 2008-12-03 RS RS20110276A patent/RS51785B/en unknown
- 2008-12-03 SI SI200830294T patent/SI2222376T1/sl unknown
- 2008-12-03 WO PCT/EP2008/066712 patent/WO2009071586A2/en active Application Filing
- 2008-12-03 GE GEAP200811833A patent/GEP20125646B/en unknown
- 2008-12-03 PL PL08857821T patent/PL2222376T3/pl unknown
- 2008-12-03 DK DK08857821.6T patent/DK2222376T3/da active
- 2008-12-03 MX MX2010006257A patent/MX2010006257A/es active IP Right Grant
- 2008-12-03 JP JP2010536439A patent/JP2011506285A/ja not_active Ceased
- 2008-12-03 AU AU2008333263A patent/AU2008333263A1/en not_active Abandoned
- 2008-12-03 PT PT08857821T patent/PT2222376E/pt unknown
- 2008-12-03 AT AT08857821T patent/ATE503473T1/de active
- 2008-12-03 KR KR1020107012217A patent/KR20100084687A/ko not_active Application Discontinuation
- 2008-12-03 CA CA2706357A patent/CA2706357C/en not_active Expired - Fee Related
- 2008-12-03 EP EP08857821A patent/EP2222376B1/en active Active
-
2010
- 2010-05-21 ZA ZA2010/03640A patent/ZA201003640B/en unknown
- 2010-05-25 IL IL205962A patent/IL205962A0/en unknown
- 2010-06-01 TN TN2010000249A patent/TN2010000249A1/fr unknown
- 2010-06-02 DO DO2010000162A patent/DOP2010000162A/es unknown
- 2010-06-03 CO CO10067247A patent/CO6280507A2/es not_active Application Discontinuation
- 2010-06-04 SV SV2010003585A patent/SV2010003585A/es not_active Application Discontinuation
- 2010-07-01 MA MA32977A patent/MA31992B1/fr unknown
-
2011
- 2011-06-21 HR HR20110468T patent/HRP20110468T1/hr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1829683A (zh) * | 2003-08-04 | 2006-09-06 | 联合股份公司格林代克斯 | 米屈肼盐及其制备方法以及基于米屈肼盐的药物组合物 |
Non-Patent Citations (1)
| Title |
|---|
| MAIJA DAMBROVA等: ""Mildronate: Cardioprotective Action through Carnitine -Lowering Effect"", 《TCM》 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fatehi‐Hassanabad et al. | The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats | |
| CA2152487C (en) | Method for treating a medical patient for cardiac trauma | |
| US4067971A (en) | Therapeutic composition | |
| US4216211A (en) | Therapeutic composition | |
| Asfar et al. | Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock | |
| Huizenga et al. | The contribution of various organs to ammonia formation: a review of factors determining the arterial ammonia concentration | |
| Liu et al. | Pyruvate in reduced osmolarity oral rehydration salt corrected lactic acidosis in sever scald rats | |
| CN101951991A (zh) | 用于治疗缺血性心脏病的3-(2，2，2-三甲基肼)丙酸盐的盐 | |
| ES2229514T3 (es) | Composicion que comprende l-carnitina o una alcanoil-l-carnitina y alcanoles de cadena larga. | |
| Singh et al. | The metabolic effects of fatal cyanide poisoning | |
| EP2070529B1 (en) | Medical use of 3-(2,2,2-trimethylhydrazinium) propionate orotate | |
| KR101342716B1 (ko) | 항-혈소판 약물, 영양 및 비타민 보충물로서의 아세틸화된아미노산 | |
| CH683966A5 (it) | Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa. | |
| AU613304B2 (en) | Continuous intravenous infusion of adenosine to human patients, a unit dosage form of adenosine and use of adenosine for the manufacture of medicaments | |
| EP2067474A1 (en) | Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate | |
| US20050153020A1 (en) | Composition comprising phosphate | |
| CH661443A5 (en) | Pharmaceutical compositions having metabolic activity | |
| Wrong et al. | Sevelamer-induced acidosis | |
| ES2364017T3 (es) | Sales de propionato de 3-(2,2,2-trimethylhydrazinium) para el tratamiento del infarto de miocardio. | |
| Nisbct | Acid-base disturbance in hypothermia | |
| Li et al. | Inhibition of NO synthesis has an additive effect on hypertension induced by ACTH in conscious rats | |
| Singla et al. | A rare case of 2, 4-Dichlorphenoxyacetic acid (2, 4-D) poisoning | |
| Baisan et al. | Nutritional dilated cardiomyopathy in cats-a report of two cases | |
| ES2210331T3 (es) | Uso de 4-amino-6-hidroxipirazol (3,4-d) pirimidina en la preparacion de un agente antihipertensivo. | |
| Chung | Nutritional Support in the Critically Ill Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110119 |